{'fraction_non_alphanumeric': 0.01903973509933775, 'fraction_numerical': 0.013245033112582781, 'mean_word_length': 5.60655737704918, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Immunohistochemical study on human epithelial ovarian carcinoma after radioimmunodetection with 131I-labelled polyclonal antibodies].

We report the results of our immunohistochemical study on the distribution and the retention time of the injected labelled antibodies in both primary and recurrent ovarian epithelial carcinomas and the regional lymph nodes, following the radioimmunodetection with injection of 131I-labelled polyclonal antibodies (including 5 cases of intravenous injection group and 35 cases of subcutaneous injection group). Six other tumors or tumor-like lesions, 8 normal ovaries and 7 normal fallopian tubes were used for control. The results demonstrated: 1. The labelled antibodies were specific for ovarian epithelial carcinoma, 2. The concentration of the labelled antibodies in the lymph node metastasis was higher in the subcutaneous injection group than in the intravenous injection group. Therefore, the subcutaneous route should be used both for imaging and radioimmunotherapy of lymph node metastasis, 3. The retention time of the antibodies in the lymph node metastasis was not more than 24 days. With this reference, the total dose of radioimmunotherapy can be calculated.